

Kjetil Steine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9223597/publications.pdf>

Version: 2024-02-01

32
papers

1,155
citations

623734

14
h-index

501196

28
g-index

32
all docs

32
docs citations

32
times ranked

1971
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. <i>European Heart Journal</i> , 2016, 37, 1671-1680.	2.2	509
2	Right Ventricular Dysfunction and Remodeling in Chronic Obstructive Pulmonary Disease Without Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1103-1111.	2.8	164
3	Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2 × 2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. <i>Circulation</i> , 2021, 143, 2431-2440.	1.6	68
4	Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During) Trial. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1021-1031.	1.2	10
5	Left Ventricular Systolic and Diastolic Function in Asymptomatic Patients With Moderate Aortic Stenosis. <i>American Journal of Cardiology</i> , 2008, 102, 897-901.	1.6	41
6	Mechanisms of diastolic intraventricular regional pressure differences and flow in the inflow and outflow tracts. <i>Journal of the American College of Cardiology</i> , 2002, 40, 983-990.	2.8	28
7	Prevalence of atrial fibrillation and cardiovascular risk factors in a 63–65 years old general population cohort: the Akershus Cardiac Examination (ACE) 1950 Study. <i>BMJ Open</i> , 2018, 8, e021704.	1.9	28
8	Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 544-552.	1.2	24
9	Heart and Brain Interactions—the Akershus Cardiac Examination (ACE) 1950 Study Design. <i>Scandinavian Cardiovascular Journal</i> , 2015, 49, 308-15.	1.2	23
10	Cardiac Troponin I and T Are Associated with Left Ventricular Function and Structure: Data from the Akershus Cardiac Examination 1950 Study. <i>Clinical Chemistry</i> , 2020, 66, 567-578.	3.2	22
11	LV systolic impairment in patients with asymptomatic coronary heart disease and type 1 diabetes is related to coronary atherosclerosis, glycaemic control and advanced glycation endproducts. <i>European Journal of Heart Failure</i> , 2007, 9, 1044-1050.	7.1	20
12	Prevalence of Cardiovascular Disease and Cardiac Symptoms: Left and Right Ventricular Function in Adults With Osteogenesis Imperfecta. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1386-1392.	1.7	20
13	Sex differences and higher upper normal limits for left atrial end-systolic volume in individuals in their mid-60s: data from the ACE 1950 Study. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 501-507.	1.2	16
14	Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SILHF study): a randomized placebo-controlled multicentre trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1239-1248.	7.1	16
15	Prediction of occult atrial fibrillation in patients after cryptogenic stroke and transient ischaemic attack: PROACTIA. <i>Europace</i> , 2022, 24, 1881-1888.	1.7	15
16	Mechanisms of ECG signs in chronic obstructive pulmonary disease. <i>Open Heart</i> , 2017, 4, e000552.	2.3	13
17	Left ventricular mechanical dispersion in a general population: Data from the Akershus Cardiac Examination 1950 study. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 183-190.	1.2	12
18	Diagnostic Thresholds for Pre-diabetes Mellitus and Diabetes Mellitus and Subclinical Cardiac Disease in the General Population: Data From the ACE 1950 Study. <i>Journal of the American Heart Association</i> , 2021, 10, e020447.	3.7	11

#	ARTICLE	IF	CITATIONS
19	Pulmonary rehabilitation to improve physical capacity, dyspnea, and quality of life following pulmonary embolism (the PeRehab study): study protocol for a two-center randomized controlled trial. <i>Trials</i> , 2021, 22, 22.	1.6	11
20	Cardiopulmonary exercise test and PaO ₂ in evaluation of pulmonary hypertension in COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 91-100.	2.3	10
21	Exercise capacity in COPD patients with exercise-induced pulmonary hypertension. <i>International Journal of COPD</i> , 2018, Volume 13, 3599-3610.	2.3	9
22	Increased LV apical untwist during preload reduction in healthy humans: an echocardiographic speckle tracking study during lower body negative pressure. <i>Physiological Reports</i> , 2015, 3, e12330.	1.7	8
23	Cardiovascular phenotype of long-term anabolic-androgenic steroid abusers compared with strength-trained athletes. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2022, 32, 1170-1181.	2.9	8
24	Assessment of Right Ventricular Afterload in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 176-185.	1.6	5
25	B-Type Natriuretic Peptide Is Associated with Indices of Left Ventricular Dysfunction in Healthy Subjects from the General Population: The Akershus Cardiac Examination 1950 Study. <i>Clinical Chemistry</i> , 2021, 67, 204-215.	3.2	5
26	Left ventricular dysfunction in COPD without pulmonary hypertension. <i>PLoS ONE</i> , 2020, 15, e0235075.	2.5	3
27	Pulmonary and cardiac variables associated with persistent dyspnea after pulmonary embolism. <i>Thrombosis Research</i> , 2021, 201, 90-99.	1.7	3
28	Associations between cardiovascular risk factors, biomarkers, and left ventricular mechanical dispersion: insights from the ACE 1950 Study. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	1
29	Left ventricular dysfunction in COPD without pulmonary hypertension. , 2020, 15, e0235075.		0
30	Left ventricular dysfunction in COPD without pulmonary hypertension. , 2020, 15, e0235075.		0
31	Left ventricular dysfunction in COPD without pulmonary hypertension. , 2020, 15, e0235075.		0
32	Left ventricular dysfunction in COPD without pulmonary hypertension. , 2020, 15, e0235075.		0